search
Back to results

A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults

Primary Purpose

Herpes Zoster

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
PEGIFNα1b
Placebo
Sponsored by
Shanghai Institute Of Biological Products
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Herpes Zoster focused on measuring Peginterferon α1b for Injection

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Must agree to and voluntarily sign a written Informed Consent prior to the study. Must be healthy males or females. Between 18 to 70 years old, inclusive. Must have a body mass index (BMI) of 19 to 26 kg/m2, inclusive, and male subject must have a minimum body weight of 50.0 kg,female subject must have a minimum body weight of 45kg. Exclusion Criteria: History of allergic or anaphylactic reactions or known allergy to any component of interferon medication including the study drug. Having abnormality in physical examination,vital signs, electrocardiogram,eye,skin(e.g., psoriasis,sarcoidosis) within screening and the abnormality is considered clinically significant as determined by the investigator. Laboratory values (platelet, hemoglobin or neutrophils)that were outside the normal range,ALT,AST or TG>1.5 fold normal range,positive test result for pregnancy,hepatitis B surface antigen(HBsAg) ,hepatitis C antibody (HCV Ab),treponema pallidum antibody or human immunodeficiency virus antibody(HIV Ab), thyroid function abnormal within screening. Having any ischemic disease,autoimmune disease,infectious disorders,history of neuropsychiatric disease (e.g., epilepsy,depression,suicidal behavior). History of any disease (gastrointestinal tract,renal,hepatic,neurologic,hematologic,endocrinologic, tumor, pulmonary, cardiovascular and/or other major disease), or organ transplantation within 6 months prior to screening. Unlikely to comply with unified diet or having difficulty to swallow. Treatment with any medication( prescription/nonpreserip drugs/vitamins/herbs ) within 30 days prior to screening. History of alcohol abuse (more than 14 units of alcohol per week, one unit of alcohol equals 360ml beer or 150ml wine or 45ml strong drinks containing 40% alcohol) within 3 months prior to screening or a positive screen test for presence for alcohol at screening or into hospital. Consuming any special diet(including dragon fruit,mango,grapefruit,etc. ) or doing strenuous exercise within 2 weeks prior to screening. Consuming alcohol or caffeine containing products(e.g., coffee,tea, coco,chocolate ) within 48 hours of dosing. Intaking any products can affecting drug absorption,distribution,excretion,metabolism. Regular smoking with consumption ≥ 5 cigarettes per day winthin 3 months prior to screening. Treatment with any interferon product within 6 months prior to screening. Participation in any other medication or device study within 3 months prior to screening. History of drug (morphine,marihuana,methamphetamine,dimethylamphetamine,ketamine,etc.) abuse or a positive screen test for presence for drugs. Having donated or lost 200 mL or more of blood within 3 months prior to screening or plan to donate blood throughout the study and within 3 months after the study. Lactating mothers,male subjects(or pairs) and female subjects have child-bearing/sperm or egg donation plan from 30 days before study to 3 months after study while unwill to practice effective birth control throughout the study. History of blood or needle phobia. Driving or operating delicated machinery throughout the study. Investigator discretion as to unsuitability

Sites / Locations

  • The first affiliated hospital of bengbu medical college

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

PEGIFNα1b 1.5 μg/kg

PEGIFNα1b 3.0 μg/kg

PEGIFNα1b 5.0μg/kg

PEGIFNα1b 6.0 μg/kg

PEGIFNα1b 7.0 μg/kg

Arm Description

8 randomized participants receive one dose PEGIFNα1b 1.5 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered

8 randomized participants receive one dose PEGIFNα1b 3.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered

8 randomized participants receive one dose PEGIFNα1b 5.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered

8 randomized participants receive one dose PEGIFNα1b 6.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered

8 randomized participants receive one dose PEGIFNα1b 7.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered

Outcomes

Primary Outcome Measures

Number of adverse events
The number of adverse events associated with the PEGIFNα1b/placebo will be collected and measured.
λz
Pharmacokinetic assessments
Tmax
Pharmacokinetic assessments
Peak Plasma Concentration (Cmax)
Pharmacokinetic assessments
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic assessments
ADA
ADA in plasma of participants for immunogenicity assessments.
Nab
Nab in plasma of participants for immunogenicity assessments.

Secondary Outcome Measures

Level of Neopterin
Plasma concentration of 2',5'-OAS(Type I,II), Neopterin

Full Information

First Posted
June 16, 2020
Last Updated
November 28, 2022
Sponsor
Shanghai Institute Of Biological Products
search

1. Study Identification

Unique Protocol Identification Number
NCT05639803
Brief Title
A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
Official Title
A Phase I,Randomized, Double-blind,Placebo Controlled,Dose Escalated, Single Adminstrated Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
July 7, 2020 (Actual)
Primary Completion Date
October 22, 2020 (Actual)
Study Completion Date
October 22, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Institute Of Biological Products

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a Phase I,randomized, double-blind, placebo controlled,dose escalated,single administrated clinical trial in Chinese healthy adult's volunteers. In the trial, it is planned to enroll 50 subjects, randomized to 5 dosage groups to receive the test drug and the placebo control.
Detailed Description
This study is a randomized, double-blind, placebo-controlled, dose-escalation, single-dose phase I clinical study, including safety tolerability assessment, pharmacokinetic studies and immunogenicity studies, to evaluate the expression level of mRNA in whole blood of 2',5'-oligoadenylate synthetase, as well as the level of Neopterin (NTP) in serum.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Herpes Zoster
Keywords
Peginterferon α1b for Injection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PEGIFNα1b 1.5 μg/kg
Arm Type
Experimental
Arm Description
8 randomized participants receive one dose PEGIFNα1b 1.5 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
Arm Title
PEGIFNα1b 3.0 μg/kg
Arm Type
Experimental
Arm Description
8 randomized participants receive one dose PEGIFNα1b 3.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
Arm Title
PEGIFNα1b 5.0μg/kg
Arm Type
Experimental
Arm Description
8 randomized participants receive one dose PEGIFNα1b 5.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
Arm Title
PEGIFNα1b 6.0 μg/kg
Arm Type
Experimental
Arm Description
8 randomized participants receive one dose PEGIFNα1b 6.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
Arm Title
PEGIFNα1b 7.0 μg/kg
Arm Type
Experimental
Arm Description
8 randomized participants receive one dose PEGIFNα1b 7.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
Intervention Type
Drug
Intervention Name(s)
PEGIFNα1b
Intervention Description
100μg/vial
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
0.5ml/vial
Primary Outcome Measure Information:
Title
Number of adverse events
Description
The number of adverse events associated with the PEGIFNα1b/placebo will be collected and measured.
Time Frame
receive PEGIFNα1b (day 1) to day 28
Title
λz
Description
Pharmacokinetic assessments
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day 15.
Title
Tmax
Description
Pharmacokinetic assessments
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day 15.
Title
Peak Plasma Concentration (Cmax)
Description
Pharmacokinetic assessments
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day 15.
Title
Area under the plasma concentration versus time curve (AUC)
Description
Pharmacokinetic assessments
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day 15
Title
ADA
Description
ADA in plasma of participants for immunogenicity assessments.
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day21.
Title
Nab
Description
Nab in plasma of participants for immunogenicity assessments.
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day21.
Secondary Outcome Measure Information:
Title
Level of Neopterin
Description
Plasma concentration of 2',5'-OAS(Type I,II), Neopterin
Time Frame
Receive PEGIFNα1b/placebo (day 1) to day15

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Must agree to and voluntarily sign a written Informed Consent prior to the study. Must be healthy males or females. Between 18 to 70 years old, inclusive. Must have a body mass index (BMI) of 19 to 26 kg/m2, inclusive, and male subject must have a minimum body weight of 50.0 kg,female subject must have a minimum body weight of 45kg. Exclusion Criteria: History of allergic or anaphylactic reactions or known allergy to any component of interferon medication including the study drug. Having abnormality in physical examination,vital signs, electrocardiogram,eye,skin(e.g., psoriasis,sarcoidosis) within screening and the abnormality is considered clinically significant as determined by the investigator. Laboratory values (platelet, hemoglobin or neutrophils)that were outside the normal range,ALT,AST or TG>1.5 fold normal range,positive test result for pregnancy,hepatitis B surface antigen(HBsAg) ,hepatitis C antibody (HCV Ab),treponema pallidum antibody or human immunodeficiency virus antibody(HIV Ab), thyroid function abnormal within screening. Having any ischemic disease,autoimmune disease,infectious disorders,history of neuropsychiatric disease (e.g., epilepsy,depression,suicidal behavior). History of any disease (gastrointestinal tract,renal,hepatic,neurologic,hematologic,endocrinologic, tumor, pulmonary, cardiovascular and/or other major disease), or organ transplantation within 6 months prior to screening. Unlikely to comply with unified diet or having difficulty to swallow. Treatment with any medication( prescription/nonpreserip drugs/vitamins/herbs ) within 30 days prior to screening. History of alcohol abuse (more than 14 units of alcohol per week, one unit of alcohol equals 360ml beer or 150ml wine or 45ml strong drinks containing 40% alcohol) within 3 months prior to screening or a positive screen test for presence for alcohol at screening or into hospital. Consuming any special diet(including dragon fruit,mango,grapefruit,etc. ) or doing strenuous exercise within 2 weeks prior to screening. Consuming alcohol or caffeine containing products(e.g., coffee,tea, coco,chocolate ) within 48 hours of dosing. Intaking any products can affecting drug absorption,distribution,excretion,metabolism. Regular smoking with consumption ≥ 5 cigarettes per day winthin 3 months prior to screening. Treatment with any interferon product within 6 months prior to screening. Participation in any other medication or device study within 3 months prior to screening. History of drug (morphine,marihuana,methamphetamine,dimethylamphetamine,ketamine,etc.) abuse or a positive screen test for presence for drugs. Having donated or lost 200 mL or more of blood within 3 months prior to screening or plan to donate blood throughout the study and within 3 months after the study. Lactating mothers,male subjects(or pairs) and female subjects have child-bearing/sperm or egg donation plan from 30 days before study to 3 months after study while unwill to practice effective birth control throughout the study. History of blood or needle phobia. Driving or operating delicated machinery throughout the study. Investigator discretion as to unsuitability
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shanghai Institute Of Biological Products Co., Ltd
Organizational Affiliation
SINOPHARM
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
The first affiliated hospital of bengbu medical college
Organizational Affiliation
Bengbu medical college
Official's Role
Principal Investigator
Facility Information:
Facility Name
The first affiliated hospital of bengbu medical college
City
Bengbu
State/Province
Anhui
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults

We'll reach out to this number within 24 hrs